×

Therapeutic drugs

Rhinopharma Ltd

http://www.rhinopharma.com

Rhinopharma Ltd is a newly formed company dedicated to finding new drug treatments for rhinitis and other respiratory diseases. In the first phase of research strategy Rhinopharma is searching for new drugs for allergic rhinitis that can be rapidly brought to clinical trial. A longer term strategic goal of the company is to develop a range of therapeutic agents based on novel polysaccharide molecules. These molecules are biological "non-stick" agents with potential applications in inflammation, cell adhesion and tissue growth. The company plans to initially commercialize one such molecule as an anti-inflammatory agent for the treatment of allergic rhinitis in a relatively easy path to market, and then progress to research and development of agents based on active fragments of heparin and related natural and synthetic compounds. The company has access to powerful new synthetic and analytical chemical techniques which it will apply to modify heparin, and related molecules, to produce novel agents for the treatment of respiratory allergies, asthma and other inflammatory diseases. In the longer term, therapeutic applications also exist for arthritis, skin and bladder diseases. As part of this strategy the company also aims to exploit anti-adhesion molecules produced by echinoderms (starfish and related organisms) as improved therapeutic agents.

  • 12/8/2013
  • 5
  • 0

Kytogenics Pharmaceuticals Ltd.

http://www.kytogenics.com

Kytogenics Pharmaceuticals, Inc. is a drug delivery and medical products company moving aggressively to market a series of clinically significant therapies. Kytogenics' key focus is the development of products for the treatment of the mucosal disorders, Interstitial Cystitis and Inflammatory Bowel Disease, major underserved medical needs each having a market potential of over $1 Billion. Kytogenics has demonstrated the effectiveness of its formulations for delivery of important drugs, and has successfully applied its technology to the delivery of peptides and other macromolecules and more recently to the delivery of drugs to mucosal tissues. Results of studies for the oral delivery of macromolecules have shown promising early success. To bring early revenue to the Company, Kytogenics completed the pre-clinical work necessary to initiate the FDA market approval process for its materials. Kytogenics has filed four 510K submissions with the FDA and expects to file an additional six during 2008. The company has also, in Phase III Pivotal Clinical Trial, a polymeric gel product for surgical adhesion prevention.

  • 12/8/2013
  • 5
  • 0

Welichem Biotech Inc.

http://www.welichem.com

Welichem Biotech Inc. (Welichem) is a development-stage biopharmaceutical company. The Company is focused on the discovery, research and development of pharmaceutical drugs for the treatment of medical needs. The Company’s prime focus is on the development of drugs for the treatment of autoimmune/inflammatory diseases and cancerous tumors. Welichem concluded two clinical trials demonstrates the potential of the drug candidates derived from its SymBiochem technology platform. (Source: ARS)

  • 12/8/2013
  • 5
  • 0

J. B. Chemicals & Pharmaceuticals Ltd

http://www.jbcpl.com

J.B. Chemicals & Pharmaceuticals Limited (JBCPL) is an India-based company that operates in the pharmaceuticals industry. The Company manufactures and markets a diverse range of pharmaceutical formulations, herbal remedies and active pharmaceutical ingredient (APIs). JBCPL exports to over 40 countries worldwide with presence in Russia, Ukraine and other Commonwealth of Independent States (CIS) countries. JBCL has a number of manufacturing plants at four locations to manufacture a diverse range of bulk drugs, intermediates, pharmaceutical specialties, radio- diagnostics and herbal remedies. During the year ended March 31, 2008 (fiscal 2008), the Company launched three new products Cilacar, the dual calcium channel blocker; Nicardia XL, which has a osmotic release technology. It also introduced Kvion- natural vitamin K27, which is a treatment for osteoporosis. (Source: ARS)

  • 12/8/2013
  • 6
  • 0

Lipoxen Plc

http://www.lipoxen.com

Lipoxen Plc is a United Kingdom-based holding company. The Company, along with its subsidiaries, is engaged in the development of drug and vaccine delivery systems and products in the fields of protein drugs, vaccines and oncology. The Company’s three delivery technologies include PolyXen, ImuXen and VesicALL. PolyXen technology uses the biopolymer polysialic acid to prolong the active life and improve the pharmacokinetics of therapeutic peptides and proteins. ImuXen technology uses liposome-based constructs to enhance the effectiveness of deoxyribonucleic acid (DNA), protein and polysaccharide vaccines. VesicALL technology is a technology that enables the formulation of anti-cancer treatments and other drugs using liposomal entrapment. (Source: ARS)

  • 12/8/2013
  • 6
  • 0

ConjuChem Inc.

http://www.conjuchem.com

ConjuChem Biotechnologies Inc. is a biotechnology company. The Company has multiple research programs in-house and has one product in clinical trials. The Company focuses on discovering and developing new drugs based on its technology platforms called Drug Affinity Complex (DACT) and Pre-formed Drug Affinity Complex (PC-DAC). The Company’s diabetes program has focused on the GLP-1 class of peptides for the treatment of Type 2 diabetes. It is pursuing the development of PC-DACTM: Exendin-4, a GLP-1 homolog combined with its PC-DACTM technology. Its diabetes program has focused on the GLP-1 class of peptides for the treatment of Type 2 diabetes. (Source: ARS)

  • 12/8/2013
  • 6
  • 0

Verona Pharma plc

http://www.veronapharma.com

Verona Pharma plc is a life sciences company focused on the research, discovery and development of new therapeutic drugs for the treatment of allergic rhinitis (hay fever) and other chronic respiratory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), as well as chronic inflammatory diseases. It has two geographical segments: United Kingdom and Canada. During the year ended December 31, 2007, the main focus for Verona Pharma was its lead clinical candidate, RPL554, an inhibitor of both phosphodiesterase 3 and 4 enzymes. Inhibition of these enzymes is associated with improved respiratory tract function and modulation of inflammatory processes. The Company’s second project is anti-inflammatory polysaccharides. This program was established to discover new types of drugs for treating inflammatory diseases, such as allergic rhinitis and asthma. (Source: ARS)

  • 12/8/2013
  • 5
  • 0

Polymedix Inc

http://www.polymedix.com

PolyMedix, Inc. is a biotechnology company focused on treating infectious diseases and acute cardiovascular disorders with synthetic small molecule compounds that mimic the activity of natural protein molecules, compounds referred to as biomimetics. Using the Company’s computational drug design technology, it has created defensin mimetic antibiotic compounds, heparin antagonist compounds (or heptagonist) and other drug compounds intended for human therapeutic use. The Company has developed PMX-30063, its principal defensin mimetic antibiotic product candidate, and other small molecule defensin mimetic antibiotics that mimic the activity of host defense proteins. It is seeking to commercialize these defensin mimetic compounds as antibiotics in a variety of forms to combat drug-resistant bacterial infections. (Source: 10-K)

  • 12/8/2013
  • 6
  • 0

Prana Biotechnology Limited

http://www.pranabio.com

Prana Biotechnology Limited is a development stage company at an early stage in the development of its pharmaceutical products that are designed to treat the underlying causes of degeneration of the brain and the eye as the aging process progresses. Other potential applications for the Company’s therapies include Huntington’s disease, Parkinson’s disease, certain cancers, age-related macular degeneration, Motor Neuron disease, Creutzfeldt-Jakob disease (the human variant of Mad Cow disease) and age-related cataracts. The Company has two wholly owned subsidiaries, Prana Biotechnology Inc. and Prana Biotechnology UK Limited. In May 2008, the Company announced that several promising candidate lead metal protein attenuating compound were demonstrating promising characteristics in animal models of Parkinson’s disease. (Source: 20-F)

  • 12/8/2013
  • 5
  • 0

Neurochem Inc.

http://www.neurochem.com

Neurochem's strategic plan focuses on the research, development and commercialization of products to provide innovation health solutions to patients suffering from serious diseases. With promising drug candidates currently in clinical trials and with expanding drug development programs, Neurochem is a company coming of age. The Company was founded in 1993 by the technology transfer office of Queen's University, Parteq Research and Development Innovations, in Kingston, Ontario, Canada, to develop and commercialize small organic molecules. These molecules, discovered by lead researchers at the university, form the basis of Neurochem's unique technology. Today, Neurochem is proud to count on the dedication of a team of close to 200 researchers, management and staff. To advance the development of its breakthrough technologies through clinical trial and commercialization phases, Neurochem has entered and continues to negotiate a variety of international R&D agreements, partnerships, collaborations and contracts with renowned scientists, researchers, academic institutions, pharmaceutical companies and contract research organizations, while maintaining the full ownership of its therapeutic rights. Our site is best viewed with IE4+ at a resolution of 1024×768.

  • 12/8/2013
  • 6
  • 0

AnorMED Inc.

http://www.anormed.com

AnorMED Inc. is a Canadian biopharmaceutical company focused on the discovery, development and commercialization of new therapeutic products for the treatment of a variety of diseases, including cancer, HIV and inflammation. Our strength lies in our medicinal chemistry capabilities that involve the application of chemistry, biochemistry and biology to generate novel chemical compounds (small molecules) with distinct pharmacological properties and therapeutic potential. Currently, we have several distinct drug candidates at various stages of development. These are divided into two categories: core products and programs, which are the focus of our in-house efforts and expense; and additional products, which are being developed by partners. AnorMED's core products and programs include: AMD3100, a stem cell mobilizer; AMD070, a new anti-HIV agent; and a research program focused on the discovery of drug candidates that target a specific class of receptors expressed on the surface of immune system cells called chemokine receptors. Specifically, the CXCR4 and CCR5 receptors that are known to be involved in a variety of diseases. The latter is a discovery program that provides further opportunities for long-term future growth. The additional products in our portfolio include: FOSRENOL, a late stage drug candidate for kidney failure patients to treat hyperphosphataemia; NX473, a cancer chemotherapy agent; the HYNIC linker, a tool for medical imaging; and Atiprimod, a potential anti-cancer agent. Our long-term business strategy involves building upon our internal drug discovery and clinical development capabilities to support the advancement of our most promising therapeutic candidates through late stage clinical trials, and to build a sales and marketing capability for select products in specific territories contingent upon available resources. We will seek to partner our product candidates at various stages of development where additional expertise or resources in clinical development and/or sales and marketing are required and reasonable commercial terms can be secured. The more advanced a product is before partnering, the better positioned we should be to negotiate terms which could include up-front and milestone payments, funding from the partner to cover all or a portion of ongoing development costs, as well as a share of revenues based on net product sales. We will also consider partnering arrangements that will enable AnorMED to participate in the marketing of the drug candidates in certain geographical areas along with arrangements that may provide a greater share of revenues in exchange for participation in the later stage development of the drug candidate. We may also evaluate opportunities to in-license a product or program to build on our core capabilities and pipeline, and will utilize alliances and strategic partnerships to expand clinical, regulatory and product development capabilities. In the short-term, we are focused on moving our lead product candidates, AMD3100 and AMD070, through clinical trials. We are currently engaged in a number of pre-commercial activities with AMD3100. In addition we are evaluating the opportunity to create our own sales and marketing team to support North American sales of this drug candidate by AnorMED. We are also conducting a series of preclinical studies with our collaborators to study the potential role AMD3100 may play in tissue repair and cancer. We expect that we will seek a partner for the worldwide commercialization of AMD070 once we have established clinical proof of principle. We will seek partnerships to support and expand the development of our drug candidates outside of North America and if we feel that we are constrained in development by available financing, resources or expertise. In addition, we are working toward identifying a clinical candidate in our CCR5 program for the treatment of HIV. Research and development within the chemokine program has resulted in the creation of a series of unique compounds targeting CXCR4 and CCR5, among other receptors. We plan to identify lead compounds from this chemokine inhibitor program to test in preclinical studies for oncology, inflammation and HIV. Collaborations and partnerships for these programs, or specific parts of these programs, will also be explored. We will continue to evaluate external product and program opportunities consistent with our business strategy and complimentary to our areas of expertise. In the context of potential growth opportunities within our own research programs we will evaluate product opportunities based on: technical/ scientific merit and challenges; business case; and resource requirements. We have several areas of activity with the potential to create substantial near-term value should we obtain positive results in our clinical programs or secure a corporate partnership that would provide third party validation of our programs and the resources to move our product candidates forward to commercialization. In addition, we are anticipating the approval and market launch of FOSRENOL this year which would provide a source of income to AnorMED.

  • 12/8/2013
  • 5
  • 0

Antigenics , Inc.

http://www.antigenics.com

Antigenics Inc. is a biotechnology company focused on developing technologies and product candidates to treat cancers and infectious diseases, primarily based on immunological approaches. The Company’s principal product candidate is Oncophage (vitespen), a patient-specific therapeutic cancer vaccine candidate that has been tested, or is being tested, in several cancer indications. The product candidate portfolio also includes QS-21 Stimulon adjuvant (QS-21), an investigational adjuvant used in vaccines under development for a variety of diseases, including but not limited to, hepatitis, human immunodeficiency virus, influenza, cancer, Alzheimer’s disease, malaria and tuberculosis; AG-707, a therapeutic vaccine program for the treatment of genital herpes, and Aroplatin, a liposomal chemotherapeutic for the treatment of solid tumors and B-cell lymphomas. (Source: 10-K)

  • 12/8/2013
  • 6
  • 0

Topigen Pharmaceuticals Inc.

http://www.topigen.com

TOPIGEN is developing several new classes of drugs and is actively progressing two drug candidates in Phase II trials for COPD and asthma. These drugs are uniquely focused on inhibiting multiple inflammation targets underlying the chronic pulmonary diseases. TOPIGEN also has a number of discovery research programs focused on the identification of novel compounds for the treatment of COPD and allergic rhinitis. By applying its knowledge and expertise in respiratory care, along with its proprietary mRNA-based chemistry, TOPIGEN is seeking to make a positive difference for patients.

  • 12/8/2013
  • 5
  • 0

ALTANA Pharma AG

http://www.altanapharma.com

Altana Pharma AG is the pharmaceutical business of Altana AG, headquartered in Konstanz, Germany. Altana Pharma concentrates on innovative pharmaceutical products in therapeutics, imaging (contrast media) and OTC medication. Therapeutics, the most important business area, is based on prescription drugs for gastrointestinal and respiratory diseases.

  • 12/8/2013
  • 5
  • 0

Biocon , Ltd.

http://www.biocon.com

Biocon Limited (Biocon) is engaged in manufacturing biotechnological products in the pharmaceutical through fermentation-based technology, and is also engaged in the formulation business. In the biopharmaceuticals segment, it focuses on the manufacture and marketing of active pharmaceutical ingredients that require fermentation and synthetic chemistry capabilities. Its statins portfolio comprises lovastatin, simvastatin, pravastatin and atorvastatin besides other statins under development. Biocon exports simvastatin to the United States, Europe, Japan and Canada; lovastatin to the United States, and pravastatin to the United States and European markets. Biocon produces mycophenolate mofetil, sirolimus and tacrolimus. It develops and markets a mix of specialty and industrial enzymes for a range of industries, including food, beverages, brewing and distilling, textiles and paper. In October 2007, the Company divested its enzymes business to Novozymes A/S. (Source: ARS)

  • 12/8/2013
  • 5
  • 0

SkyePharma PLC

http://www.skyepharma.com

SkyePharma PLC develops pharmaceutical products benefiting from world-leading drug delivery technologies that provide easier-to-use and more effective drug formulations. There are now eleven approved products incorporating SkyePharma's technologies in the areas of oral, injectable, inhaled and topical delivery, supported by advanced solubilisation capabilities.

  • 12/8/2013
  • 5
  • 0

Takeda Chemical Industries , Ltd.

http://www.takeda.com

Takeda Pharmaceutical Company Limited is a Japan-based company engaged in the pharmaceutical business. The Company operates in three business segments. The Pharmaceutical segment is engaged in the manufacture and sale of pharmaceutical products, such as therapeutic substances for diabetes, circulatory drugs, digestive system drugs, hormonal agents, osteoporosis drugs, antibiotic agents, allergy medications and vitamin drops. The Health Care segment is engaged in the manufacture and sale of general drugs and medicines, as well as quasi drugs. The Others segment is involved in the manufacture and sale of chemical reagents and chemical products. The Company has 47 subsidiaries and 17 associated companies.

  • 12/8/2013
  • 5
  • 0

Myriad Genetics , Inc.

http://www.myriad.com

Myriad Genetics, Inc. is a healthcare company focused on the development and marketing of molecular diagnostic and therapeutic products. The Company’s molecular diagnostic business focuses on the analysis of genes and their alterations to assess an individual’s risk for developing disease later in life (predictive medicine) and to assess a patient’s risk of disease progression, disease recurrence, drug toxicity, and drug response (personalized medicine). As of June 30, 2008, the Company had launched five commercial molecular diagnostic products, including both predictive medicine and personalized medicine products. Its commercial molecular diagnostic products include BRACAnalysis, COLARIS, COLARIS AP, MELARIS and THERAGUIDE 5-FU. It markets these products through its own person sales force in the United States and it has entered into marketing collaborations with other organizations in selected foreign countries. On April 10, 2008, the Company acquired NaturNorth Technologies, LLC. (Source: 10-K)

  • 12/8/2013
  • 5
  • 0

AstraZeneca PLC

http://www.astrazeneca.com

AstraZeneca PLC discovers, develops, manufactures and markets prescription pharmaceuticals, biologics and vaccines for principal areas of healthcare, including cardiovascular, gastrointestinal, neuroscience, oncology, respiratory and inflammation, and infection. The Company's products include Arimidex, Crestor, Nexium, Seroquel and Symbicort. It has 29 manufacturing sites in 20 countries. During the year ended December 31, 2007, the Company acquired MedImmune, Inc. (Source: 20-F)

  • 12/8/2013
  • 6
  • 0

Note

Not found any data